染色体微阵列与外显子测序在先天性心脏病胎儿中的综合评估
本研究对360例超声心动图检出先天性心脏病(CHD)的非选择性单胎胎儿进行染色体微阵列分析(CMA)和外显子测序(ES)。总体遗传学阳性诊断率为23.3%,其中CMA检出染色体异常占16.7%,ES额外检出序列变异占6.7%。非孤立性CHD的遗传变异检出率显著高于孤立性CHD(38.6% vs 18.8%,P<0.001)。
要点
- CHD胎儿总体遗传学阳性率为23.3%,CMA检出16.7%,ES额外检出6.7%。
- 非孤立性CHD遗传变异检出率显著高于孤立性CHD(38.6% vs 18.8%,P<0.001)。
- CMA未发现异常时,无论CHD是否孤立,均应建议行ES检测。
核心结论
- CHD胎儿中染色体异常占16.7%,ES额外检出序列变异占6.7%。
- CMA未见异常或致病性CNV时,无论CHD是否孤立,均应提供ES检测。
研究设计与样本
- 所有胎儿先常规行CMA检测非整倍体和拷贝数变异(CNV),CMA未见非整倍体或致病性CNV者再行ES。
主要发现
- 84例(23.3%)胎儿获得阳性遗传学诊断,其中CMA检出染色体异常60例(16.7%),ES额外检出序列变异24例(6.7%)。
- 非孤立性CHD的致病性及可能致病性遗传变异检出率为38.6%(32/83),显著高于孤立性CHD的18.8%(52/277)(P<0.001)。
- 遗传缺陷患病率最高见于房室间隔缺损(36.8%)、室间隔缺损伴或不伴房间隔缺损(28.4%)、圆锥动脉干畸形(22.2%)或右心室流出道梗阻(20.0%)。
- 发现两个新错义突变(c.2447G>C,p.Arg816Pro;c.1171C>T,p.Arg391Cys)及PLD1变异导致的新表型。
关键数值与推荐
- 总体阳性遗传诊断率23.3%(84/360)。
- CMA检出染色体异常率16.7%(60/360)。
- ES额外检出序列变异率6.7%(24/360)。
- 非孤立性CHD遗传变异检出率38.6%(32/83),孤立性CHD为18.8%(52/277),P<0.001。
临床怎么用
- 对CHD胎儿应先行CMA检测非整倍体和致病性CNV。
- CMA未见异常时,无论CHD是否孤立,均应建议行ES检测以额外检出序列变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate comprehensively, using chromosomal microarray analysis (CMA) and exome sequencing (ES), the prevalence of chromosomal abnormalities and sequence variants in unselected fetuses with congenital heart defect (CHD) and to evaluate the potential diagnostic yields of CMA and ES for different CHD subgroups. METHODS: This was a study of 360 unselected singleton fetuses with CHD detected by echocardiography, referred to our department for genetic testing between February 2018 and December 2019. We performed CMA, as a routine test for aneuploidy and copy number variations (CNV), and then, in cases without aneuploidy or pathogenic CNV on CMA, we performed ES. RESULTS: Overall, positive genetic diagnoses were made in 84 (23.3%) fetuses: chromosomal abnormalities were detected by CMA in 60 (16.7%) and sequence variants were detected by ES in a further 24 (6.7%) cases. The detection rate of pathogenic and likely pathogenic genetic variants in fetuses with non-isolated CHD (32/83, 38.6%) was significantly higher than that in fetuses with isolated CHD (52/277, 18.8%) (P < 0.001), this difference being due mainly to the difference in frequency of aneuploidy between the two groups. The prevalence of a genetic defect was highest in fetuses with an atrioventricular septal defect (36.8%), ventricular septal defect with or without atrial septal defect (28.4%), conotruncal defect (22.2%) or right ventricular outflow tract obstruction (20.0%). We also identified two novel missense mutations (c.2447G>C, p.Arg816Pro; c.1171C>T, p.Arg391Cys) and a new phenotype caused by variants in PLD1. CONCLUSIONS: Chromosomal abnormalities were identified in 16.7% and sequence variants in a further 6.7% of fetuses with CHD. ES should be offered to all pregnant women with a CHD fetus without chromosomal abnormality or pathogenic CNV identified by CMA, regardless of whether the CHD is isolated. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Qiao F, Wang Y, Zhang C, et al. Comprehensive evaluation of genetic variants using chromosomal microarray analysis and exome sequencing in fetuses with congenital heart defect. Ultrasound Obstet Gynecol. 2021. PMID: 33142350. doi:10.1002/uog.23532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。